Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page shows a new revision label. It updates from Revision: v3.5.2 to Revision: v3.5.3, signaling a software release rather than substantive changes to the study data or content.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No user-facing content or layout changes are evident.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision: v3.5.0 was added and v3.4.3 was removed.SummaryDifference0.0%

- Check62 days agoChange DetectedA backend version update shows revision v3.4.3 replacing v3.4.2. No visible changes to study content or user-facing features.SummaryDifference0.0%

- Check91 days agoChange DetectedRevision: v3.4.2 is now shown on the page. Notices about government funding lapse and an older Revision: v3.4.1 have been removed.SummaryDifference0.4%

- Check98 days agoChange DetectedA government funding lapse notice about site status was added, and the page now displays the updated revision version 3.4.1 (replacing 3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.